<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To define incidence of HBV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in patients with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">blood diseases</z:e> caused by blood components transfusion; correlation between <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> rate and <z:e sem="disease" ids="C1533163" disease_type="Disease or Syndrome" abbrv="">blood disease</z:e> nosological entity, intensity of hemoreplacement therapy, time of <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B incubation period in patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> after the diagnosis and initiation of polychemotherapy (PCT) </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIAL AND METHODS: In 2000-2007 a prospective clinicoepidemiological trial was made to detect markers of HBV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> among 303 patients 15 to 76 years of age treated in the department of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> chemotherapy of N.N </plain></SENT>
<SENT sid="2" pm="."><plain>Burdenko Military Hospital for <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoid and myeloblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> in a blastic crisis, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> in blast transformation, <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative diseases</z:e> with bone marrow affection </plain></SENT>
<SENT sid="3" pm="."><plain>Statistic processing was performed with standard methods </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: HBV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> markers were detected in 30 (9.9%) of 303 examinees </plain></SENT>
<SENT sid="5" pm="."><plain>Among the infected patients there were 16 (53.4%) patients with different variants of <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo>, 12 (40.0%) with different immunophenotypes of <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>, 1 (3.3%) patient with <z:hpo ids='HP_0011009'>acute</z:hpo> biphenotypical <z:hpo ids='HP_0001909'>leukemia</z:hpo> and 1 (3.3%) with <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>HBV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> was registered in patients 2 to 32 months after the beginning of the treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Most of the patients - 23 (74%) of 30 - were infected with HBV within the first year after hematological diagnosis and PCT induction course </plain></SENT>
<SENT sid="8" pm="."><plain>HBV was diagnosed within treatment year two in 5 (16%) patients and within year three after PCT in 3 (10%) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: High incidence of HBV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> points to a high epidemiological risk of hemoreplacement therapy, unsatisfactory quality of donor blood testing and necessity of updating methods of donor <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> detection </plain></SENT>
<SENT sid="10" pm="."><plain>To lower the risk of HBV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> it is necessary to perform vaccine prophylaxis of <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B before PCT </plain></SENT>
</text></document>